<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02082756</url>
  </required_header>
  <id_info>
    <org_study_id>2013KTZB03-02-01B</org_study_id>
    <nct_id>NCT02082756</nct_id>
  </id_info>
  <brief_title>Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment</brief_title>
  <official_title>Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment：an Open-label, Multicenter，Randomized, Prospective，Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine&#xD;
      Hydrochloride on lowering glucose and delaying progress to diabetes in patients with&#xD;
      prediabetes and to detect the potential mechanism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gut microbiota may play an important role in patients with prediabetes. Berberine, which is&#xD;
      usually used as an antibiotic drug, has been reported a potential glucose-lowering effect in&#xD;
      vitro and in vivo studies. Bifidobacterium, as a familiar probiotics, can modulate gut&#xD;
      microbiota and improve glucose and lipid metabolism in animal experiments. Therefore, the aim&#xD;
      of this study is to assess the beneficial effects of Bifidobacterium and Berberine&#xD;
      Hydrochloride on lowering glucose and delaying progress to diabetes in patients with&#xD;
      prediabetes and to detect the potential mechanism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The sponsor have not enough money to support this trial&#xD;
  </why_stopped>
  <start_date type="Anticipated">November 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 2-hour postprandial blood glucose between baseline to week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>2-hour postprandial blood glucose are measured at baseline and week 12 during a 2 hour-meal test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut microbiome composition</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>Faecal bacterial composition determined from microbiological cultures and deep metagenomic next-generation sequencing of bacterial DNA in feces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>From baseline to week 12</time_frame>
    <description>Standardized questionaries regarding gastrointestinal function are filled out at each study visit (0, 4, 8 and 12 weeks after randomization) to detect possible adverse effects of antibiotics. In addition, subjects are given a calendar and informed to write down any symptom or illness during the study period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>Bifidobacterium viable pharmaceutics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Berberine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Berberine Hydrochloride, 0.5g, 2/day, 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lifestyle counseling</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bifidobacterium viable pharmaceutics</intervention_name>
    <arm_group_label>Bifidobacterium viable pharmaceutics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine Hydrochloride</intervention_name>
    <arm_group_label>Berberine Hydrochloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained before any trial-related activities&#xD;
&#xD;
          -  Male or female between 18 and 70 years of age&#xD;
&#xD;
          -  19≤Body mass index(BMI)≤30kg/m2&#xD;
&#xD;
          -  No participate in any clinical trial at least 3 months&#xD;
&#xD;
          -  Fasting blood glucose(FBG)&lt;7.0mmol/L and 2-hour postprandial blood&#xD;
             glucose(2hPBG)&lt;11.1mmol/L&#xD;
&#xD;
          -  Females in child-bearing period should be given birth control&#xD;
&#xD;
          -  No severe disease about heart, lung and kidney&#xD;
&#xD;
          -  Ability and willingness to adhere to the protocol including performance of&#xD;
             self-monitored blood glucose (SMBG) profiles according to the protocol;&#xD;
&#xD;
          -  Subject is likely to comply with the Investigators instruction.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes mellitus or type 1 diabetes mellitus&#xD;
&#xD;
          -  Females of childbearing potential who are pregnant，breastfeeding or intend to become&#xD;
             pregnant or are not using adequate contraceptive methods&#xD;
&#xD;
          -  Impaired liver function, defined as Aspartate aminotransferase(AST) or Alanine&#xD;
             transaminase(ALT)&gt; 2 times upper limit of normal (central laboratory)&#xD;
&#xD;
          -  Impaired renal function, defined as serum-creatinine≥133μmol/L&#xD;
&#xD;
          -  Uncontrolled treated/untreated severe hypertension (systolic blood pressure≥160mmHg&#xD;
             and /or diastolic blood pressure≥95mmHg)&#xD;
&#xD;
          -  Chronic gastrointestinal diseases&#xD;
&#xD;
          -  Cancer and medical history of cancer (except basal cell skin cancer or squamous cell&#xD;
             skin cancer)&#xD;
&#xD;
          -  Any clinically significant disease or disorder, which in the Investigator's opinion&#xD;
             could interfere with the results of the trial&#xD;
&#xD;
          -  Mental incapacity, psychiatric disorder, unwillingness or language barriers precluding&#xD;
             adequate understanding or co-operation, including subjects not able to read and write&#xD;
&#xD;
          -  Previous participation in this trial. Participation is defined as randomized.&#xD;
             Re-screening of screening failures is allowed only once within the limits of the&#xD;
             recruitment period&#xD;
&#xD;
          -  Known or suspected hypersensitivity to trial products or related products&#xD;
&#xD;
          -  Known or suspected abuse of alcohol, narcotics or illicit drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiu Ji, Ph.D..M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology, Xijing Hospital, Fourth Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an,</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 323rd Hospital of People's Liberation Army</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710054</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaanxi Provincial People's Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710068</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>March 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2014</study_first_posted>
  <last_update_submitted>November 11, 2018</last_update_submitted>
  <last_update_submitted_qc>November 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prediabetes</keyword>
  <keyword>Berberine Hydrochloride</keyword>
  <keyword>Bifidobacterium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

